1/31/2013

The FDA approved Kynamro, or mipomersen, as an add-on treatment to lipid-lowering drugs and diet for patients with homozygous familial hypercholesterolemia. Due to risks of liver problems, the once-weekly injectable drug will carry a boxed warning.

Related Summaries